First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221

NCT02675465 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

29

Enrollment

INDUSTRY

Sponsor class

Conditions

Pompe Disease

Interventions

DRUG: ATB200
DRUG: AT2221

Sponsor

Amicus Therapeutics